Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report a novel, easy-to-manufacture 'exposed-core' vaginal ring that provides sustained release of the protein microbicide candidate 5P12-RANTES, an experimental chemokine analogue that potently blocks the HIV CCR5 coreceptor.
|
30731150 |
2019 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasma samples from 130 subjects with TB (HIV<sup>+</sup>/TB<sup>+</sup>) and 130 subjects without TB (HIV<sup>+</sup>/TB<sup>-</sup>) were tested for concentration of the following markers: CCL5, C-reactive protein (CRP), interleukin (IL)-6, IL12-p70, IL-18, IL-27, interferon-γ-induced protein-10 (IP-10), procalcitonin (PCT), and soluble urokinase-type plasminogen activator receptor (suPAR).
|
30800697 |
2019 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, we described a new type of silicone elastomer vaginal ring offering sustained release of the protein molecule 5P12-RANTES, a potent experimental chemokine analogue that potently blocks the HIV CCR5 coreceptor.
|
30999049 |
2019 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
O-GalNAcylation of RANTES Improves Its Properties as a Human Immunodeficiency Virus Type 1 Entry Inhibitor.
|
29202246 |
2018 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that compounds that increase the endogenous production of CCL5 may be used to reduce the pathogenesis of HIV-associated neurocognitive disorders.
|
25623966 |
2015 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To study whether two functional single nucleotide polymorphisms of the CC chemokine ligand 5 (CCL5) gene could affect susceptibility to pulmonary tuberculosis (TB) in a human immunodeficiency virus negative genetically homogeneous population, containing newly diagnosed patients with active disease.
|
19335954 |
2009 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using real-time PCR we quantified the colonic mucosal mRNA expression of selected proinflammatory and regulatory (gamma interferon [IFN-gamma], tumor necrosis factor alpha [TNF-alpha], and interleukin-2 [IL-2], IL-4, IL-6, and IL-10) and HIV-inhibitory (IL-16, CCL3, and CCL5) cytokines for 10 HIV-infected patients before and during 9 months of highly active antiretroviral therapy (HAART).
|
18573939 |
2008 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, the primate host CCL3, CCL4 and CCL5 gene expression was evaluated in response to simian-human immunodeficiency virus (SHIV) infection in rhesus macaque model.
|
17684570 |
2007 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The products of these genes and of CCL5 (encoding RANTES, i.e., regulated on activation, normal T expressed and secreted) can block or interfere with human immunodeficiency virus type 1 (HIV-1) infection through competitive binding to chemokine (C-C motif) receptor 5 (CCR5).
|
17330138 |
2007 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated the effect of RANTES polymorphisms on human immunodeficiency virus type 1 (HIV-1) disease progression in an urban population of Uganda.
|
16897666 |
2006 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
An increased frequency of SDF-1 3'A and RANTES-403A genotypes was present in EU individuals but the difference was not statistically significant when compared to healthy and HIV infected controls.
|
16865553 |
2006 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, PSC-RANTES is a potent inhibitor of R5 HIV infection in immature LC, suggesting that it may be useful as a topical microbicide to block sexual transmission of HIV.
|
15220435 |
2004 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that a role exists for RANTES neutralization sensitivity of HIV-1 in AIDS pathogenesis.
|
12964118 |
2003 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection.
|
12080383 |
2002 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
RANTES production from CD4+ lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression.
|
11343219 |
2001 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Levels of RANTES production by CD4+ and CD8+ T cells and CD8-mediated inhibition of human immunodeficiency virus type 1 gene expression before initiation of antiretroviral therapy were significantly associated with an undetectable virus load maintained for 1 year (P<.05).
|
10669333 |
2000 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
|
10775626 |
2000 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antigen-specific production of RANTES, macrophage inflammatory protein (MIP)-1alpha, and MIP-1beta in vitro is a correlate of reduced human immunodeficiency virus burden in vivo.
|
10979927 |
2000 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chemokine receptors have been identified as coreceptors for viral entry into susceptible target cells, and several members of the beta chemokine subfamily of cytokines, MIP-1alpha, MIP-1beta, and RANTES, have been identified as the major human immunodeficiency virus (HIV)-suppressive factors produced by activated CD8+ T lymphocytes.
|
10972089 |
2000 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
RANTES, a beta-chemokine, can suppress human immunodeficiency virus (HIV) as well as simian immunodeficiency virus (SIV) infections in T-lymphocyte cultures in vitro.
|
10364494 |
1999 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.
|
10196243 |
1999 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
NK cells freshly isolated from HIV-infected individuals had a high number of mRNA copies for MIP-1alpha and RANTES.
|
9649576 |
1998 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The measurement of RANTES produced by heparinized whole blood in response to HIV-1 antigens appears as a potentially valuable tool to assess the defect of type 1 immune response in individuals infected with HIV-1 and to define whether the absence of a RANTES response may play a role in the increased rate of HIV-1 replication.
|
9716114 |
1998 |